Sanofi’s OX40L Blocker Shows Efficacy and Safety in AD With Every 12-Week Dosing

Amlitelimab, Sanofi’s investigational OX40-ligand (OX40L) blocker, showed improvements in skin clearance and disease severity in patients with AD as a monotherapy and in combination with topical therapies.